CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）在三阴性乳腺癌中的作用及过继性细胞疗法的研究进展
英文原题：The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.
查看英文原题
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
乳腺癌的治疗效果与雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER2）的表达密切相关。三阴性乳腺癌（TNBC）缺乏ER、PR和HER2表达，治疗选择有限，预后较差。TIL（肿瘤浸润淋巴细胞）（TILs）通过影响肿瘤微环境发挥促进或抵抗肿瘤的作用，被认为是乳腺癌进展中的关键调节因子。然而，迄今为止，TNBC的治疗方法（如手术、化疗和放疗）疗效尚不满意。本文综述了不同类型TILs在TNBC中的作用以及过继细胞疗法的研究进展，旨在为TNBC提供新的治疗途径。
展开英文摘要原文
The treatment outcome of breast cancer is closely related to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Triple-negative breast cancer (TNBC) lacking ER, PR, and HER2 expression has limited treatment options and a poor prognosis. Tumor-infiltrating lymphocytes (TILs) play a role in promoting or resisting tumors by affecting the tumor microenvironment and are known as key regulators in breast cancer progression.
However, treatments for TNBC (e. g. , surgery, chemotherapy and radiotherapy) have non-satisfaction's curative effect so far. This article reviews the role of different types of TILs in TNBC and the research progress of adoptive cell therapy, aiming to provide new therapeutic approaches for TNBC.
论文信息
- 作者
- Li R、Cao L
- 单位
- Oncology Department, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 37275874 · DOI 10.3389/fimmu.2023.1194020
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →